Lakefront Biotherapeutics (LKFT)
28.59
-0.02
(-0.07%)
USD |
NASDAQ |
Jun 11, 09:48
Lakefront Biotherapeutics EPS Diluted (Quarterly) : 0.2457 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.2457 |
| December 31, 2025 | 13.81 |
| September 30, 2025 | -3.584 |
| June 30, 2025 | -1.819 |
| March 31, 2025 | -2.450 |
| December 31, 2024 | 0.4097 |
| September 30, 2024 | -0.8407 |
| June 30, 2024 | 0.1468 |
| March 31, 2024 | 1.486 |
| September 30, 2023 | 0.4264 |
| June 30, 2023 | 0.0842 |
| March 31, 2023 | 0.3779 |
| December 31, 2022 | -3.210 |
| September 30, 2022 | 0.3296 |
| June 30, 2022 | -0.3081 |
| March 31, 2022 | -0.2275 |
| December 31, 2021 | 0.2851 |
| September 30, 2021 | -1.162 |
| June 30, 2021 | -1.184 |
| March 31, 2021 | -0.2362 |
| December 31, 2020 | -1.055 |
| September 30, 2020 | -1.464 |
| June 30, 2020 | -1.974 |
| March 31, 2020 | -0.8617 |
| December 31, 2019 | -1.977 |
| Date | Value |
|---|---|
| September 30, 2019 | 6.704 |
| June 30, 2019 | -0.9684 |
| March 31, 2019 | -1.012 |
| December 31, 2018 | 0.3081 |
| September 30, 2018 | 0.3179 |
| June 30, 2018 | -0.5002 |
| March 31, 2018 | -0.8972 |
| December 31, 2017 | -0.6946 |
| September 30, 2017 | -0.852 |
| June 30, 2017 | -0.8273 |
| March 31, 2017 | -0.3106 |
| December 31, 2016 | 1.045 |
| September 30, 2016 | -0.5817 |
| June 30, 2016 | -0.0899 |
| March 31, 2016 | 0.8711 |
| December 31, 2015 | -1.598 |
| September 30, 2015 | -0.7797 |
| December 31, 2005 | -0.0832 |
| September 30, 2005 | -0.2927 |
| June 30, 2005 | 0.00 |
| March 31, 2005 | 0.00 |
| December 31, 2004 | 0.0429 |
| September 30, 2004 | 0.00 |
| June 30, 2004 | -0.1515 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.612 |
| Karyopharm Therapeutics, Inc. | -1.236 |
| Ocugen, Inc. | -0.0586 |
| Nkarta, Inc. | -0.3748 |
| Zenas BioPharma, Inc. | -1.456 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 16.25M |
| Revenue (Quarterly) | 7.582M |
| Total Expenses (Quarterly) | -8.663M |
| Enterprise Value | -1.543B |
| Gross Profit Margin (Quarterly) | 25.95% |
| Earnings Yield | 30.28% |
| Operating Earnings Yield | 34.89% |
| Normalized Earnings Yield | 40.18 |